1. Li, Xuanxuan, Liu, Huan, Zhou, Xue, Zeng, Manting, Zhu, Hong. 2023. PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer. In Clinical epigenetics, 15, 123. doi:10.1186/s13148-023-01538-1. https://pubmed.ncbi.nlm.nih.gov/37533109/
2. Fang, Chao, Wang, Sai-Ying, Liou, Yu-Ligh, Ouyang, Wen, Duan, Kai-Ming. 2019. The promising role of PAX1 (aliases: HUP48, OFC2) gene methylation in cancer screening. In Molecular genetics & genomic medicine, 7, e506. doi:10.1002/mgg3.506. https://pubmed.ncbi.nlm.nih.gov/30636379/
3. Miao, Danxiu, Ren, Jie, Jia, Yanhan, Huang, Huizhe, Gao, Rui. 2024. PAX1 represses canonical Wnt signaling pathway and plays dual roles during endoderm differentiation. In Cell communication and signaling : CCS, 22, 242. doi:10.1186/s12964-024-01629-3. https://pubmed.ncbi.nlm.nih.gov/38664733/
4. Singh, Priyanka, Bhadada, Sanjay Kumar, Arya, Ashutosh Kumar, Brandi, Maria Luisa, Rao, Sudhaker Dhanwada. . Aberrant Epigenetic Alteration of PAX1 Expression Contributes to Parathyroid Tumorigenesis. In The Journal of clinical endocrinology and metabolism, 107, e783-e792. doi:10.1210/clinem/dgab626. https://pubmed.ncbi.nlm.nih.gov/34453169/
5. Yakici, Nalan, Kreins, Alexandra Y, Catak, Mehmet Cihangir, Davies, E Graham, Baris, Safa. 2023. Expanding the clinical and immunological phenotypes of PAX1-deficient SCID and CID patients. In Clinical immunology (Orlando, Fla.), 255, 109757. doi:10.1016/j.clim.2023.109757. https://pubmed.ncbi.nlm.nih.gov/37689091/